NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: May 9, 2024

Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024